CUPERTINO, Calif., Dec. 17, 2024 /PRNewswire/ -- Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback